Who founded Azalea Therapeutics?

Azalea Therapeutics was founded by Jennifer Doudna, Rodolphe Barrangou, Krishnendu Roy, Connor Tsuchida in 2023.

Who are Azalea Therapeutics's investors?

Azalea Therapeutics's investors include Third Rock Ventures, RA Capital, Sozo Ventures, Yosemite.

Where is Azalea Therapeutics headquartered?

Azalea Therapeutics is headquartered in San Francisco, US.

Azalea Therapeutics

San Francisco, US · Founded 2023 · 36 employees on LinkedIn · 4 known investors

Find your way into Azalea Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Azalea Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine Learning Biotech Medical Devices

Founders & leadership

Azalea Therapeutics was founded in 2023 by Jennifer Doudna, Rodolphe Barrangou, Krishnendu Roy, and Connor Tsuchida.

Jennifer DoudnaCo-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley

Rodolphe BarrangouCo-founder, Associate Professor of Medicine, UCSF

Krishnendu RoyCo-founder, Professor of Bioengineering, Stanford University

Connor Tsuchida Scientific Co-FounderConnor Tsuchida is a bioengineer who earned his PhD under Jennifer Doudna at UC Berkeley and UCSF, with prior training at the University of Washington, Pfizer, Harvard University, and NYU School of Medicine. He is scientific cofounder of Azalea Therapeutics, which develops in vivo genome editing therapies for cancer immunotherapy.30 Under 30 2024

Investors · 4

Third Rock Ventures✓ confirmed by Azalea TherapeuticsBoston · $100K – $5M

How we know: Third Rock Ventures's portfolio page · a partner's Signal profile · funding news · press coverage · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · press coverage · Not right? Tell us

Sozo VenturesreportedRedwood City

How we know: press coverage · Not right? Tell us

YosemitereportedSan Francisco

How we know: press coverage · Not right? Tell us

Related companies · 1

Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.

Companies working in the same space as Azalea Therapeutics.

In the news

Azalea Therapeutics Raises $82M in Series A Fundingfinsmes.com · Nov 2025

Frequently asked questions

What does Azalea Therapeutics do?: Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
Who founded Azalea Therapeutics?: Azalea Therapeutics was founded by Jennifer Doudna, Rodolphe Barrangou, Krishnendu Roy, Connor Tsuchida in 2023.
Who are Azalea Therapeutics's investors?: Azalea Therapeutics's investors include Third Rock Ventures, RA Capital, Sozo Ventures, Yosemite.
Where is Azalea Therapeutics headquartered?: Azalea Therapeutics is headquartered in San Francisco, US.